Vanguard Group Discloses Stakes in Avadel Pharmaceuticals

The Vanguard Group, Inc. has released a disclosure under Rule 8.3 of the Irish Takeover Panel Act concerning Avadel Pharmaceuticals plc. As of December 18, 2025, Vanguard holds 5.98% of Avadel’s US$0.01 ordinary shares, totaling 5,824,861 shares, with no reported short positions or derivatives.

The disclosure indicates recent transactions involving Avadel securities. Vanguard purchased 49,719 shares at a price of 21.42 USD per share and sold 6,661 shares at the same price. No cash-settled or stock-settled derivative transactions were reported. Moreover, there are no indemnity, option agreements, or arrangements suggesting trading incentives.

This standard disclosure ensures compliance with regulations for firms holding significant equity positions in relevant securities. No additional agreements impacting voting rights or future transactions are disclosed.